EL7.AI
StocksMediumUpdated×3•Originally published 3 August 2026•Updated 3 August 2026•
1 min read

Twist Bioscience Reports Mixed Q3: Revenue Beats Estimates Despite Wider EPS Loss

Key Facts

1Twist Bioscience reported a GAAP EPS of -$0.56, missing analyst estimates by $0.08.
2The company's revenue reached $118.4M, beating expectations by $3.86M.

Reflecting the dynamic shifts in the biotechnology landscape, Twist Bioscience reported mixed fiscal third-quarter 2026 results, posting a GAAP loss per share of $0.56 which missed estimates by $0.08. However, the company demonstrated robust top-line momentum with revenue reaching $118.4 million, a 23.2% year-over-year increase that exceeded analyst expectations.

The growth was underpinned by a 39% surge in DNA Synthesis and Protein Solutions revenue to $56.6 million, while Next-Generation Sequencing (NGS) applications grew 12% to approximately $61.8 million. The company maintains a healthy balance sheet characterized by a current ratio of 2.67 and a low debt-to-equity ratio of 0.21, supporting its revised full-year revenue guidance of $456 million to $457 million.

Investors should track the company's margin trajectory following the U.S. Federal Reserve's decision to hold interest rates at 3.75% as of July 29, 2026.